Frequent expression of the high molecular, 673-bp CD44v3,v8-10 variant in colorectal adenomas and carcinomas

International Journal of Molecular Medicine

Volumn 24, Issue 5, 2009, Pages 677-683

  Kopp, Reinhard ^a,c   Fichter, M ^a,b   Schalhorn, G ^a,b   Danescu, J ^b   Classen, S ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c Klinikum Harlaching   (Germany)

Author keywords

CD44v3; Colorectal adenomas

Indexed keywords

CD44V ANTIGEN; CD44V10 ANTIGEN; CD44V3 ANTIGEN; CD44V4 ANTIGEN; CD44V5 ANTIGEN; CD44V6 ANTIGEN; CD44V7 ANTIGEN; CD44V8 ANTIGEN; CD44V9 ANTIGEN; COMPLEMENTARY DNA; LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CELL STRAIN HT29; COLON CARCINOGENESIS; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; DNA SEQUENCE; EXON; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; MOLECULAR SIZE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN VARIANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOMA; ANTIGENS, CD44; BASE PAIRING; BASE SEQUENCE; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA;

EID: 70350752040     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000279     Document Type: Article

References (41)

1. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
2. Segditsas S and Tomlinson I: Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 25: 7531-7537, 2006.
3. Al-Sukhni W, Aronson M and Gallinger S: Hereditary colorectal cancer syndromes: familial adenomatous polyposis and lynch syndrome. Surg Clin North Am 88: 819-844, 2008.
4. Ladeda V, Aquirre Ghiso JA and Bal de Kier Joffe E: Function and expression of CD44 during spreading, migration, and invasion of murine catcinoma cells. Exp Cell Res 242: 515-527, 1998.
5. Herrlich P, Pals S and Ponta H: CD44 in colon cancer. Eur J Cancer 31 (Suppl A): 1110-1112, 1995.
6. Kim H, Yang XL, Rosada C, Hamilton SR and August JT: CD44 expression in colorectal adenomas is an early event occuring prior to K-ras and p53 gene mutation. Arch Biochem Biophys 310: 504-507, 1994.
7. Tölg C, Hofmann M, Herrlich P and Ponta H: Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acid Res 21: 1225-1229, 1993.
8. Isacke CM and Yarwood H: The hyaluronan receptor, CD44. Int J Biochem Cell Biol 34: 718-721, 2002.
9. Ponta H, Sherman L and Herrlich PA: CD44: from adhesion molecules to signalling regulators. Nat Rec Mol Cell Biol 4: 33-45, 2003.
10. Heldin P, Karousou E, Bernert B, Porsch H, Nishitsuka K and Skandalis SS: Importance of hyaluronan-CD44 interaction in inflammation and tumorigenesis. Connect Tissue Res 49: 215-218, 2008.
11. Mulder JWR, Kruyt PM, Sewnath M, Oosting J, Seldenrijk CA, Weidema WF, Offerhaus GJA and Pals ST: Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 344: 1470-1472, 1994.
12. Friedrichs K, Franke F, Lisboa BW, Zügler G, Gille I, Terpe HJ, Hölzel F, Maass H and Günthert U: CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 55: 5424-5433, 1995.
13. Jackson DG, Schenker T, Waibel R, Bell JI and Stahel RA: Expresssion of alternatively spliced forms of the CD44 extracellular-matrix receptor on human lung carcinomas. Int J Cancer (Suppl) 8: 110-115, 1994.
14. Wielenga VJM, Heider KH, Offerhaus GJA, Adolf GR, van den Berg FM, Ponta H, Herrlich P and Pals ST: Expresssion of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 53: 4754-4756, 1993.
15. Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I, Matzku S, Wenzel A, Ponta H and Herrlich P: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65: 13-24, 1991.
16. Sy MS, Guo YJ and Stamenkovic I: Inhibition of tumor growth in vivo with a soluble CD44-immunglobulin fusion protein. J Exp Med 176: 623-627, 1992.
17. Van Weering DHJ, Baas PD and Bos L: A PCR-based method for the analysis of human CD44 splice products. PCR Methods Appl 3: 100-106, 1993.
18. Fichter M, Hinrichs R, Eissner G, Scheffer B, Classen S and Ueffing M: Expression of CD44 isoforms in neuroblastoma cells is regulated by PI 3-kinase and protein kinase C. Oncogene 14: 2817-2824, 1997.
19. Fox SB, Fawcett J, Jackson DG, Collins I, Gatter KC, Harris AL, Gearing A and Simmons DL: Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res 54: 4539-4546, 1994.
20. Imazeki F, Yokusuka O, Yamaguchi T, Ohto M, Isono K and Omata M: Expression of variant CD44-messenger RNA in colorectal adenocarcinomas and adenomatous polyps in humans. Gastroenterology 110: 362-368, 1997.
21. Wielenga VJ, van der Voort R, Taher TE, Smit L, Beuling EA, van Krimpen C, Spaargaren M and Pals ST: Expression of c-Met and heparan-sulfate proteoglycan forms of CD44 in colorectal cancer. Am J Pathol 157: 1563-1673, 2000.
22. Dall P, Heider KH, Hekele A, von Minckwitz G, et al: Surface protein expression and messenger RNA-splicing analysis of CD44 in uterine cervical cancer and normal cervical epithelium. Cancer Res 54: 3337-3341, 1994.
23. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E and Kosma AV: Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis. Scand J Gastroenterol 33: 301-309, 1998.
24. Rosenberg WMC, Prince C, Kaklamanis L, Fox SB, Jackson DG, Simmons DL, Chapman RW, Trowell JM, Jewell DP and Bell JI: Increased expression of CD44v6 and CD44v3 in ulcerative colitis but not colonic Crohn's disease. Lancet 345: 1205-1209, 1995.
25. Hofmann M, Rudy W, Günthert U, Zimmer GS, Zawadzki V, Zöller M, Lichtner RB, Herrlich P and Ponta H: A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastatic specific variants of CD44 in CREF cells. Cancer Res 53: 1516-1521, 1993.
26. Heider KH, Hofmann M, Hors E, van den Berg F, Ponta H, Herrlich P and Pals ST: A human homologue of the rat metastasisassociated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol 120: 227-233, 1993.
27. Jamal HH, Cano-Gauci DF, Buick R and Filmus J: Activated ras and src induce CD44 overexpression in rat intestinal epithelial cells. Oncogene 9: 417-423, 1994.
28. Cheng C and Sharp PA: Regulation of CD44 alternative splicing by Srm160 and its potential role in tumor cell invasion. Mol Cell Biol 26: 362-370, 2006.
29. Kopp R, Fichter M, Assert R, Pfeiffer AF and Classen S: Butyrate-induced alterations of phosphoinositide metabolism, protein kinase C activity and reduced CD44 variant expresion in HT-29 colon cancer cells. Int J Mol Med 23: 639-649, 2009.
30. Barishat M, Levi I, Benharroch D and Schwartz B: Butyrate down-regulates CD44 transcription and liver colonisation in a highly metastatic human colon carcinoma cell line. Br J Cancer 87: 1314-1320, 2002.
31. Cheng C, Yaffe MB and Sharp PA: A positive feedback loop couples ras activation and CD44 alternative splicing. Genes Dev 20: 1715-1720, 2006.
32. Lakshman M, Subramaniam V, Rubenthiran U and Jothy S: CD44 promotes resistance to apoptosis in human colon cancer cells. Exp Mol Pathol 77: 18-25, 2004.
33. Kuniyasu H, Oue N, Sutsumi M, Tahara E and Yasui W: Heparan sulfate enhances invasion by human colon carcinoma cell lines through expression of CD44 variant exon 3. Clin Cancer Res 7: 4067-4072, 2001.
34. Benett KL, Jackson DG, Simon JC, Tanczos E, Peach R, Mdrell B, Stamenkovic I, Plowman G and Aruffo A: A CD44 isoform containing exon v3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol 128: 687-698, 1995.
35. Kuniyasu H, Chihara Y, Kubozoe T and Takahashi T: Coexpression of CD44v3 and heparanase is correlated with metastasis of human colon cancer. Int J Mol Med 10: 333-337, 2002.
36. Du L, Wang H, He L, Zhang J, Ni B, Wang X, Jin H, Cahuzac N, Mehrpour M, Lu Y and Chen Q: CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 14: 6751-6760, 2008.
37. Zeilstra J, Joosten SP, Dokter M, Verwiel E, Spaargaren M and Pals ST: Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/ +) mice attenuates intestinal tumorigenesis. Cancer Res 68: 3655-3661, 2008.
38. Bates RC, Edwards NS, Burns CF and Fisher DE: A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/ Akt in colon carcinoma cells. Cancer Res 61: 5275-5283, 2001.
39. Harada N, Mizoi T, Kinouchi M, Hoshi K, Ishii S, Shiiba K, Saaki I and Matsuno S: Introduction of antisense CD44s cDNA down-regulates expression of overall isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinomas cells. Int J Cancer 91: 67-95, 2001.
40. Subramaniam V, Vincent IR, Galikjan M and Jothy S: Suppression of human colon cancer tumors in nude mice by siRNA CD44 gene therapy. Exp Mol Pathol 83: 332-340, 2007.
41. Smith A, Collaco R and Trempe JP: AAV vector delivery to cells in culture. Meth Mol Biol 246: 167-177, 2004.